Camrelizumab in patients with advanced non-squamous non-small cell lung cancer: a cost-effective analysis in China

OBJECTIVE: Camrelizumab is a selective, humanised, high-affinity IgG(4) kappa monoclonal antibody against programmed cell death 1 that shows effective antitumour activity with acceptable toxicity in multiple tumour types. The CameL trial demonstrated that camrelizumab plus chemotherapy (CC) signific...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Qian, Zheng, Hanrui, Su, Na, Li, Qiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9362787/
https://www.ncbi.nlm.nih.gov/pubmed/36194670
http://dx.doi.org/10.1136/bmjopen-2022-061592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9362787/
https://www.ncbi.nlm.nih.gov/pubmed/36194670
http://dx.doi.org/10.1136/bmjopen-2022-061592

Ejemplares similares